OVERVALUEDNASDAQ · Healthcare

Entera Bio Ltd.

ENTX

FAIR PRICE VALUATION

49.8%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$1.16

FAIR PRICE

$0.58

MARGIN

$0.58

UNDERVALUEDFAIROVERVALUED

P/E Ratio

8.3x

What is P/E? →

Div. Yield

N/A

ROE

-0.6%

Average

Market Cap

$51M

Small-cap

COMING SOON

Get notified when ENTX's fair price changes

Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.

iOS and Android · Free tier available

KEY FACTS

CEO

Miranda J. Toledano

COUNTRY

IL

HEADQUARTERS

Jerusalem

SECTOR

Healthcare

EXCHANGE

NASDAQ

METHODOLOGY

How we calculate ENTX's fair price

Entera Bio Ltd.'s fair price of $0.58 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.16, ENTX trades 49.8% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ENTX's risk profile.

RELATIVE · 30%

Comparing ENTX's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for ENTX, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate ENTX's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for ENTX.

Explore on Bulios

FAQ

What is the fair price of ENTX?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Entera Bio Ltd. is $0.58. At the current market price of $1.16, ENTX trades 49.8% above its calculated fair value.

Is ENTX overvalued or undervalued?+

Entera Bio Ltd. is currently overvalued based on our valuation model. The stock trades at $1.16, which is 49.8% above the fair price of $0.58. The P/E ratio of 8.3x is a key metric in the valuation.

How often is ENTX's fair price updated?+

We update fair price calculations for ENTX daily after market close. The current fair price of $0.58 incorporates the latest market data and sector multiples.

What factors affect ENTX's fair price calculation?+

ENTX's fair price of $0.58 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 8.3x, ROE of -0.6%.

Is ENTX a good buy right now?+

At $1.16, ENTX trades 49.8% above our fair value estimate of $0.58. The stock is currently overvalued. ROE stands at -0.6% (average). Fair Price Index provides valuation data — always do your own research before investing.

Does ENTX pay dividends?+

ENTX does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.